Viking Therapeutics Is A Buy For Some Investors, But Beware The Sizeable Risks

Core Viewpoint - Viking Therapeutics, Inc. (NASDAQ: VKTX) is likely to be acquired by a large pharmaceutical firm due to the strong efficacy of its weight-loss drug VK2735 [1] Group 1 - The drug VK2735 has shown strong efficacy, which positions the company favorably for potential acquisition [1]